Bristol-Myers Squibb chooses UCLA as latest research partner
pharmafile | December 14, 2015 | News story | Manufacturing and Production, Research and Development | BMS, Bristol-Myers Squibb, University of California Los Angeles, rare malignancies, ucla
Pharma firm Bristol-Myers Squibb is entered into a new collaboration agreement with the University of California Los Angeles (UCLA) as part of a research program in the US.
The company’s Immuno-Oncology Rare Population Malignancy (I-O RPM) research program is an initiative BMS is running with academic-based cancer research centres, focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.
The US firm has already agreed a deal with Johns Hopkins University, to conduct a range of early stage clinical studies, as part of the program. BMS is also working with the Moffatt Cancer Centre in Florida as part of the program.
Bristol-Myers Squibb and the David Geffen School of Medicine at UCLA will conduct a range of early phase clinical studies as part of the I-O RPM research program, and Bristol-Myers Squibb will fund positions within UCLA’s fellowship program in the UCLA Division of haematology and oncology.]
“The I-O RPM research program is an important complement to Bristol-Myers Squibb’s broad research and development program for immuno-oncology,” says Dr Laura Bessen, who is head of US medical at Bristol-Myers Squibb. She adds: “We look forward to working with UCLA in an effort to continue advancing the science in this innovative field of research and cancer treatment.”
The I-O RPM research program focuses on significant areas of high unmet need marked by poor outcomes among patients with rare population malignancies: a subpopulation within a higher incident disease population. These patients have aggressive disease with an increased potential for early metastasis to multiple sites and/or are initially refractory or subject to early recurrences with conventional cancer therapies.
Lilian Anekwe
Related Content
Meteor Biotech opens site at UCLA to support biotech research
South Korean spatial omics specialist, Meteor Biotech, has announced the opening of its first international …
Elekta and BMS partner for digital treatment for melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan …
BMS acquires Mirati Therapeutics for $4.8bn
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a …
